Cite
Olsalazine is not superior to placebo in maintaining remission of inactive Crohn's colitis and ileocolitis: a double blind, parallel, randomised, multicentre study.
MLA
Mahmud, N., et al. “Olsalazine Is Not Superior to Placebo in Maintaining Remission of Inactive Crohn’s Colitis and Ileocolitis: A Double Blind, Parallel, Randomised, Multicentre Study.” Gut, vol. 49, no. 4, Oct. 2001, pp. 552–56. EBSCOhost, https://doi.org/10.1136/gut.49.4.552.
APA
Mahmud, N., Kamm, M. A., Dupas, J. L., Jewell, D. P., O’Morain, C. A., Weir, D. G., & Kelleher, D. (2001). Olsalazine is not superior to placebo in maintaining remission of inactive Crohn’s colitis and ileocolitis: a double blind, parallel, randomised, multicentre study. Gut, 49(4), 552–556. https://doi.org/10.1136/gut.49.4.552
Chicago
Mahmud, N, M A Kamm, J L Dupas, D P Jewell, C A O’Morain, D G Weir, and D Kelleher. 2001. “Olsalazine Is Not Superior to Placebo in Maintaining Remission of Inactive Crohn’s Colitis and Ileocolitis: A Double Blind, Parallel, Randomised, Multicentre Study.” Gut 49 (4): 552–56. doi:10.1136/gut.49.4.552.